1 Raineri I, Bongiovanni M, Bode-Lesniewska B, Bode PK, Bubendorf L, Kilgus S, et al. Prévention du cancer du col de l’utérus: dépistage HPV en première intention versus cytologie. Forum Med Suisse. 2019;19(37–38):608–10.
2 Frey Tirri B, Petignat P, Jacot-Guillarmod M, Mueller M, Fehr M, Kind AB. Recommandations pour la prévention du cancer du col de l’utérus. SSGO. Avis d’expert No 50, 1er Mars 2018.
https://www.sggg.ch/fileadmin/user_upload/Formulardaten/EB_akt_50_Gebaermutterhalskrebsvorsorge_01.03.18_Franz.pdf.
3 Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. Vaccine. 2008;26 Suppl 10:K29–41. doi:10.1016/j.vaccine.2008.06.019.
4 Arbyn M, Haelens A, Desomer A, Verdoodt F, Thiry N, Francart J, et al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2015. KCE Reports 238. D/2015/10.273/17.
5 Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.
6 Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385–94.
7 Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
8 Katki HA, KinneyWK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.
9 Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30:3044–50.
10 Elfström KM, Smelov V, Johansson AL, Eklund C, Nauclér P, Arnheim-Dahlström L, et al. Long-term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;348.
11 Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs. cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43–52.
12 Kim JJ, Burger EA, Regan C, Sy S. Screening for Cervical Cancer in Primary Care. A Decision Analysis for the US Preventive Services Task Force. JAMA. 2018;320(7):706–14.
13 Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96–e107.
14 Vassilakos P, Poncet A, Catarino R, Viviano M, Petignat P, Combescure C. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland. Gynecol Oncol. 2019;153(1):92–9.
doi:10.1016/j.ygyno.2019.01.021.
15 Lees BF, Erickson BK, Huh WK. Cervical cancer screening: Evidence behind the guidelines. Am J Obstet Gynecol. 2016;214(4):438–43.
16 Vassilakos P, Viviano M, Mathevet P, Petignat P. Aktualisierte Screening-Richlinien für Gebärmutterhalskrebs in der Schweiz. Die Antworten auf 3 grundlegende Fragen. info@gynäkologie. 2019 Oktober;9(5).
17 American Society of Cytopathology Multidisciplinary Steering Committee. Facing the future of cytopathology: discerning the future needs of our profession. 2010.
https://www.cytopathology.org/wp-content/dynamic_uploads/3439.pdf. (
https://ascpresidentsmessage.wordpress.com/) (Accessed March 2020).
18 Cahill LA. Opportunities for cytotechnologists in a changing environment. Cancer Cytopathol. 2014;122(7):479–80.
19 Simms KT, Steinberg J, Caruana M et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol. 2019;20:394–407.